<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Gabapentin - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <link rel="icon" type="image/svg+xml" href="/Dyo-s-Dubious-Domain/assets/logo.svg">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚ÜÅE<a href="/dyos-domain/depressants/">Depressants</a> ‚ÜÅE<span>Gabapentin</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üíä Gabapentin</h1>
        <h2 class="chemical-name">1-(aminomethyl)cyclohexaneacetic acid</h2>
         <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Gabapentin" 
                data-category="Depressants" 
                data-chemical="1-(aminomethyl)cyclohexaneacetic acid">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Neurontin</span> ‚Ä¢ <span>Gralise</span> ‚Ä¢ <span>Horizant</span> ‚Ä¢ <span>FusePaq Fanatrex</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Gabbies</span> ‚Ä¢ <span>Johnnies</span> ‚Ä¢ <span>Morontin</span> ‚Ä¢ <span>Gaba</span>
            </div>
            <div class="name-category">
              <h4>Slang Terms</h4>
              <span>Nerve Pills</span> ‚Ä¢ <span>G's</span> ‚Ä¢ <span>300s</span> ‚Ä¢ <span>Gabba</span>
            </div>
            <div class="name-category">
              <h4>Chemical</h4>
              <span>GBP</span> ‚Ä¢ <span>1-AMCA</span> ‚Ä¢ <span>CI-945</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category depressant">Depressant</span>
          <span class="legal-status prescription">Prescription</span>
          <span class="duration long">6-8 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/Dyo-s-Dubious-Domain/assets/substances/gabapentin.jpg" alt="Gabapentin capsules" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇâH‚ÇÅ‚ÇáNO‚ÇÅE/p>
            <p>MW: 171.24 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pharmaceutical Forms</h4>
          <ul>
            <li><strong>Capsules:</strong> White/cream capsules, various sizes (100mg, 300mg, 400mg)</li>
            <li><strong>Tablets:</strong> White oval tablets (600mg, 800mg) often scored</li>
            <li><strong>Oral solution:</strong> Clear to slightly yellow liquid (250mg/5ml)</li>
            <li><strong>Extended-release:</strong> Specialized formulations (Gralise, Horizant)</li>
            <li><strong>Markings:</strong> Imprinted with manufacturer codes and dosage</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Common Street Presentations</h4>
          <ul>
            <li><strong>300mg capsules:</strong> Most commonly diverted, white/yellow caps</li>
            <li><strong>Loose pills:</strong> Often sold individually or in small quantities</li>
            <li><strong>Powder:</strong> Rarely - contents of opened capsules</li>
            <li><strong>Blister packs:</strong> Legitimate pharmacy packaging</li>
          </ul>
        </div>
        
        <div class="identification-tips">
          <h4>üîç Identification Tips</h4>
          <p><strong>Legitimate pills:</strong> Professional pharmaceutical appearance with clear imprints</p>
          <p><strong>Diverted medication:</strong> Usually in original packaging or pharmacy bottles</p>
          <p><strong>Counterfeits:</strong> Rare due to low value, but possible with poor quality imprints</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">300-600mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">600-900mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">900-1800mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">1800-3000mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Heavy</span>
          <span class="dose-amount">3000mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Dosage Considerations</h4>
        <ul>
          <li><strong>Bioavailability:</strong> Decreases with higher doses (saturable absorption)</li>
          <li><strong>Staggered dosing:</strong> Take 300mg every 30-60 minutes for better absorption</li>
          <li><strong>Food effects:</strong> Fatty foods can increase absorption</li>
          <li><strong>Tolerance:</strong> Develops rapidly with daily use</li>
          <li><strong>Medical range:</strong> 300-3600mg daily for epilepsy/neuropathy</li>
          <li><strong>Recreational range:</strong> 1200-2400mg (higher doses show diminishing returns)</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Absorption Note:</strong> Gabapentin has saturable absorption - taking large doses at once is inefficient. Stagger doses for maximum effect.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-2:00</span>
          <span class="effect">Onset - subtle relaxation begins</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-4:00</span>
          <span class="effect">Peak - euphoria, sociability, anxiety relief</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+4:00-8:00</span>
          <span class="effect">Plateau - sustained calming effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+8:00-12:00</span>
          <span class="effect">Comedown - gradual return to baseline</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÅEPositive Effects</h4>
          <ul>
            <li>Anxiety relief and calm</li>
            <li>Mild euphoria and mood lift</li>
            <li>Increased sociability</li>
            <li>Pain relief (neuropathic)</li>
            <li>Muscle relaxation</li>
            <li>Improved sleep quality</li>
            <li>Reduced inhibitions</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùÅENegative Effects</h4>
          <ul>
            <li>Drowsiness and sedation</li>
            <li>Dizziness and coordination issues</li>
            <li>Memory impairment</li>
            <li>Slurred speech</li>
            <li>Weight gain (long-term)</li>
            <li>Cognitive dulling</li>
            <li>Withdrawal symptoms</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Despite being a GABA analog, gabapentin does NOT directly interact with GABA receptors. Instead, it binds to the Œ±2Œ¥ subunit of voltage-gated calcium channels (VGCCs), reducing calcium influx and subsequently decreasing neurotransmitter release. This mechanism underlies both its therapeutic effects and recreational potential.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±2Œ¥-1 VGCC subunit</strong></span>
            <span class="affinity">High affinity (primary target)</span>
            <span class="function">Reduces excitatory neurotransmitter release</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±2Œ¥-2 VGCC subunit</strong></span>
            <span class="affinity">Moderate affinity</span>
            <span class="function">Pain modulation, anxiety reduction</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>GABA-A receptors</strong></span>
            <span class="affinity">No direct binding</span>
            <span class="function">Indirect enhancement via reduced glutamate</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>AMPA receptors</strong></span>
            <span class="affinity">Indirect modulation</span>
            <span class="function">Reduced excitatory transmission</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA receptors</strong></span>
            <span class="affinity">Indirect reduction</span>
            <span class="function">Neuroprotective effects, reduced excitotoxicity</span>
          </div>
        </div>

        <h4>Absorption & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Absorption mechanism:</strong> Large amino acid transporter (LAT1) - saturable transport</p>
          <p><strong>Bioavailability:</strong> 60% at 300mg, decreases to 35% at 1600mg (dose-dependent)</p>
          <p><strong>Peak plasma:</strong> 2-3 hours after oral dose</p>
          <p><strong>Half-life:</strong> 5-7 hours (longer in elderly or kidney impairment)</p>
          <p><strong>Metabolism:</strong> Not metabolized - excreted unchanged by kidneys</p>
          <p><strong>Protein binding:</strong> <3% (very low)</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <ul>
          <li><strong>Saturable absorption:</strong> Taking more doesn't always mean more effect</li>
          <li><strong>No hepatic metabolism:</strong> Safe in liver disease, fewer drug interactions</li>
          <li><strong>Renal elimination:</strong> Dose adjustment needed in kidney disease</li>
          <li><strong>BBB penetration:</strong> Crosses via LAT1 transporter (not passive diffusion)</li>
          <li><strong>Tolerance mechanism:</strong> Downregulation of Œ±2Œ¥ subunits with chronic use</li>
          <li><strong>Withdrawal potential:</strong> Physical dependence possible with regular use</li>
        </ul>

        <h4>Therapeutic vs Recreational Mechanisms</h4>
        <div class="therapeutic-vs-recreational">
          <p><strong>Therapeutic effects:</strong> Chronic dosing stabilizes neuronal excitability, reduces neuropathic pain</p>
          <p><strong>Recreational effects:</strong> Acute high-dose calcium channel blockade produces euphoria and disinhibition</p>
          <p><strong>Paradox:</strong> Can be both calming (therapeutic) and euphoric (recreational) depending on dose and tolerance</p>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†ÔøΩEÔøΩESafety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Critical Warnings</h4>
          <ul>
            <li><strong>Withdrawal risk:</strong> Can cause severe withdrawal including seizures</li>
            <li><strong>Respiratory depression:</strong> Dangerous with opioids or alcohol</li>
            <li><strong>Driving impairment:</strong> Significant coordination and judgment issues</li>
            <li><strong>Suicidal ideation:</strong> FDA black box warning for increased suicide risk</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°ÔøΩEÔøΩEPrecautions</h4>
          <ul>
            <li>Never stop abruptly after regular use - taper slowly</li>
            <li>Avoid driving or operating machinery</li>
            <li>Don't mix with alcohol or other depressants</li>
            <li>Monitor for mood changes or depression</li>
            <li>Stay hydrated and avoid overheating</li>
            <li>Use lowest effective dose</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Contraindications</h4>
        <p><strong>Use with extreme caution if you have:</strong> Kidney disease, respiratory problems, depression, bipolar disorder, or substance abuse history. Elderly users are at higher risk for serious side effects.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏ÅEDrug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Dangerous</h4>
          <ul>
            <li><strong>Opioids:</strong> Severe respiratory depression, potentially fatal</li>
            <li><strong>Benzodiazepines:</strong> Compounded CNS depression</li>
            <li><strong>Alcohol:</strong> Increased sedation, respiratory risk</li>
            <li><strong>Barbiturates:</strong> Dangerous CNS depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° Risky</h4>
          <ul>
            <li><strong>Morphine:</strong> Increased gabapentin absorption and effects</li>
            <li><strong>Hydrocodone:</strong> Enhanced CNS depression</li>
            <li><strong>Muscle relaxants:</strong> Additive sedation</li>
            <li><strong>Sleep aids:</strong> Compounded drowsiness</li>
          </ul>
        </div>
        
        <div class="interaction caution">
          <h4>üü† Use Caution</h4>
          <ul>
            <li><strong>Antacids:</strong> Reduce gabapentin absorption (space doses)</li>
            <li><strong>Antihistamines:</strong> Increased drowsiness</li>
            <li><strong>Antidepressants:</strong> Monitor for mood changes</li>
            <li><strong>Caffeine:</strong> May partially counteract sedative effects</li>
          </ul>
        </div>
      </div>
      
      <div class="interaction-note">
        <h4>üí° Interaction Note</h4>
        <p>Gabapentin has relatively few drug-drug interactions due to lack of hepatic metabolism. However, it potentiates other CNS depressants significantly.</p>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏ÅELegal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United States</h4>
            <p><strong>Prescription Only</strong> - Schedule V in some states (Kentucky, Michigan, etc.). Growing recognition as drug of abuse.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE United Kingdom</h4>
            <p><strong>Prescription Only Medicine (POM)</strong> - Legal with prescription, illegal to supply without license.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Canada</h4>
            <p><strong>Prescription Required</strong> - Schedule F drug, available only with prescription.</p>
          </div>
          <div class="jurisdiction">
            <h4>ÔøΩEÔøΩE Australia</h4>
            <p><strong>Schedule 4</strong> - Prescription only medicine, controlled access.</p>
          </div>
        </div>
        
        <div class="legal-trends">
          <h4>üìà Legal Trends</h4>
          <p>Increasing states are classifying gabapentin as a controlled substance due to abuse potential and involvement in overdose deaths. Expect tighter controls in coming years.</p>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1977</span>
          <p>Synthesized by Pfizer as a GABA analog for epilepsy treatment</p>
        </div>
        <div class="history-event">
          <span class="year">1993</span>
          <p>FDA approval for epilepsy as Neurontin</p>
        </div>
        <div class="history-event">
          <span class="year">2002</span>
          <p>Approved for postherpetic neuralgia (nerve pain)</p>
        </div>
        <div class="history-event">
          <span class="year">2004</span>
          <p>Pfizer pays $430M fine for illegal off-label marketing</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Emergence as drug of abuse, especially combined with opioids</p>
        </div>
        <div class="history-event">
          <span class="year">2019</span>
          <p>Multiple states begin classifying as controlled substance</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Cultural Impact</h4>
        <p>Gabapentin represents the "prescription drug abuse epidemic" phenomenon - a legitimate medication that found its way into recreational use. Its popularity stems from easy availability, legal gray areas, and synergistic effects with other substances, particularly opioids.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Alcohol Use Disorder</h4>
          <p>Studies showing gabapentin reduces alcohol cravings and withdrawal symptoms, potentially offering an alternative to traditional treatments.</p>
        </div>
        
        <div class="research-item">
          <h4>Chronic Pain Management</h4>
          <p>Ongoing research into optimal dosing strategies and combination therapies for neuropathic pain conditions.</p>
        </div>
        
        <div class="research-item">
          <h4>Abuse Liability</h4>
          <p>Investigation into gabapentin's abuse potential, particularly in combination with opioids and its role in overdose deaths.</p>
        </div>
        
        <div class="research-item">
          <h4>Anxiety Disorders</h4>
          <p>Off-label use studies for generalized anxiety disorder and social anxiety, though efficacy remains controversial.</p>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Medical Information</h4>
        <ul>
          <li><a href="https://www.drugs.com/gabapentin.html">Drugs.com</a> - Comprehensive medical information</li>
          <li><a href="https://medlineplus.gov/">MedlinePlus</a> - NIH drug information</li>
          <li><a href="https://www.rxlist.com/">RxList</a> - Professional drug reference</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction</h4>
        <ul>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - User experiences and safety</li>
          <li><a href="https://erowid.org/">Erowid</a> - Experience reports and information</li>
          <li><a href="https://bluelight.org/">Bluelight</a> - Harm reduction community</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Treatment</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Substance abuse treatment locator</li>
          <li><a href="https://na.org/">Narcotics Anonymous</a> - 12-step recovery program</li>
          <li><a href="https://www.benzowithdrawal.com/">Benzo Withdrawal</a> - Tapering support community</li>
        </ul>
      </div>
    </div>
  </div>

</div>


    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/Dyo-s-Dubious-Domain/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>